The Est\u00e9e Lauder Companies has taken a minority stake in luxury clinical skin care brand 111Skin as it sharpens its focus on science-backed beauty and treatment-led innovation.<\/p>\n
Founded in 2012 by plastic and reconstructive surgeon Dr Yannis Alexandrides, 111Skin was originally developed to help accelerate patients\u2019 healing following procedures.<\/p>\n
The brand now sells more than 30 products, led by its Black Diamond and Reparative collections, and is distributed through luxury retail, ecommerce and high-end spa channels.<\/p>\n
Its stockists include Harrods, Bluemercury, Nordstrom, Mandarin Oriental and Aman, while its direct-to-consumer business accounts for around 20 per cent of sales.<\/p>\n
The Est\u00e9e Lauder Companies president and chief executive St\u00e9phane de La Faverie said skin care was entering \u201ca new phase\u201d shaped by the convergence of procedures, longevity and beauty.<\/p>\n
He said consumers were increasingly looking for products that deliver \u201cvisible, treatment-inspired results\u201d.<\/p>\n
\u201c111Skin exemplifies this shift, translating Dr Alexandrides\u2019 more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy,\u201d he said.<\/p>\n
In 2025, North America accounted for around 40 per cent of 111Skin\u2019s sales, while the brand also has an established presence in the UK, China, Europe and Asia Pacific.<\/p>\n
Following the investment, Alexandrides will remain actively involved in the business and will continue to lead 111Skin alongside its existing management team.<\/p>\n
Alexandrides and co-founder Eva Alexandrides said: \u201cWe are thrilled to be partnering with The Est\u00e9e Lauder Companies and to unlock an exciting new chapter for 111Skin.\u201d<\/p>\n